InterMune (ITMN) 14.21 -0.29

InterMune, Inc.
(ITMN) 14.21 -0.29

Last Trade:	14.21	Day Range:	14.10 - 14.6912
Trade Time:	12:02PM	52wk Range:	10.67 - 51.71
Prev. Close:	14.50	Market Cap:	930.86M
Open:	14.59	Div Yield:	0
Volume:	676876	PE:	80
EPS:	1.80

The Latest On ITMN

Morgan Stanley Maintains InterMune at Equal-weight, Lowers PT from $18 to $17 2/13/12 11:32am

Brean Murray Carret Reiterates Buy, $42 Target on InterMune 2/10/12 9:48am

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12 3:49pm

Goldman Reiterates Neutral On InterMune, Lowers PT 1/6/12 12:39pm

Goldman Sachs Lowers PT on InterMune to $18 1/6/12 7:00am

InterMune Reports Preliminary Fourth Quarter 2011 Esbriet Revenue and Other Recent Business Highlights 1/5/12 7:03am

UPDATE: Oppenheimer Lowers PT on InterMune to $38 1/4/12 10:18am

Oppenheimer Lowers PT on InterMune to $38 1/4/12 7:12am

IQWIG Publishes Early Benefit Assessment for Pirfenidone 12/16/11 6:55am

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11 5:47pm

End-of-Day Market Summary for December 15, 2011 12/15/11 4:29pm

Afternoon Movers; Markets Moved Higher 12/15/11 4:08pm

Morgan Stanley Maintains InterMune at Equal-weight, Lowers PT from $18 to $17 2/13/12

Brean Murray Carret Reiterates Buy, $42 Target on InterMune 2/10/12

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Goldman Reiterates Neutral On InterMune, Lowers PT 1/6/12

Goldman Sachs Lowers PT on InterMune to $18 1/6/12

InterMune Reports Preliminary Fourth Quarter 2011 Esbriet Revenue and Other Recent Business Highlights 1/5/12

UPDATE: Oppenheimer Lowers PT on InterMune to $38 1/4/12

Oppenheimer Lowers PT on InterMune to $38 1/4/12

IQWIG Publishes Early Benefit Assessment for Pirfenidone 12/16/11

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

End-of-Day Market Summary for December 15, 2011 12/15/11

Afternoon Movers; Markets Moved Higher 12/15/11

Just What The Doctor Ordered: 4 ETFs For Biotech M&A 1/9/12

Goldman Reiterates Neutral On InterMune, Lowers PT 1/6/12

Benzinga's M&A Chatter for Thursday December 15, 2011 12/15/11

Mama Mia Market! 11-09-2011 11/9/11

Stocks To Watch For September 13 9/13/11

Top Percentage Gainers and Losers as of 12pm 5/10/11 (FONR, TRAK, CKXE, CPE, FFHL MED, PTRY, GENE,BMTI, HEAT, PANL, USAT, HOLI, ITMN, VRML) 5/10/11

InterMune Hits 52-Week High (ITMN) 4/14/11

DepoMed Up Over 100% in 2010 On InterMune Sympathy? (DEPO, ITMN) 12/28/10

Big Pharma in Frenzy of Drug Deals 12/21/10

InterMune Trading Up 6.22% Pre-Market (ITMN) 12/20/10

Benzinga's Volume Movers (EQIX, TTES, BMC, ITMN) 10/7/10

Benzinga's Top Pre-Market NASDAQ Gainers (ALVR, ITMN, FSLR, AKRX) 10/7/10

Morgan Stanley Maintains InterMune at Equal-weight, Lowers PT from $18 to $17 2/13/12

Brean Murray Carret Reiterates Buy, $42 Target on InterMune 2/10/12

Goldman Reiterates Neutral On InterMune, Lowers PT 1/6/12

Goldman Sachs Lowers PT on InterMune to $18 1/6/12

UPDATE: Oppenheimer Lowers PT on InterMune to $38 1/4/12

Oppenheimer Lowers PT on InterMune to $38 1/4/12

End-of-Day Market Summary for December 15, 2011 12/15/11

Brean Murray Lowers PT on InterMune to $42 11/4/11

Disclosure Insight Maintains Medium Risk on InterMune 11/1/11

Morgan Stanley Maintains Equal-Weight on InterMune 9/29/11

Morgan Stanley Raises PT on InterMune to $28 9/29/11

Credit Suisse Initiating Coverage On Intermune 9/15/11

Trade ITMN
NOW!

Partner Headlines

InterMune Widens Loss, Sales Dip - Analyst Blog 2/10/12

InterMune 4Q Esbriet Sales Snapshot - Analyst Blog 1/9/12

8 Stocks Rising on Huge Volume 1/5/12

Dendreon: Provenge Q4 Sales Beat 1/5/12

Biotech 2012 Kickoff Party: Investor Preview 1/4/12

5 Oversold Stocks To Watch (BBY,FSLR,ITMN,CREE,IBN) 12/20/11

5 Biotech Stocks for 2012 12/9/11

Press Releases

InterMune Reports Fourth Quarter and Full Year 2011 Financial Results and Business Highlights 2/9/12 Newswire Story

InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development 2/9/12 Newswire Story

InterMune to Release Fourth Quarter and Full Year Financial Results on February 9 2/2/12 Newswire Story

Critical Alerts for General Motors, Transocean Ltd., Citrix, SodaStream, and InterMune Released by Seven Summits Research 1/6/12 Newswire Story

InterMune to Present at J. P. Morgan Healthcare Conference 1/5/12 Newswire Story

InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights 1/5/12 Newswire Story

InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5 1/4/12 Newswire Story

IQWIG Publishes Early Benefit Assessment for Pirfenidone 12/15/11 Newswire Story

InterMune to Present at Oppenheimer & Co. 22nd Annual Healthcare Conference on Dec. 14 12/7/11 Newswire Story

InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 11/3/11 Newswire Story

InterMune Appoints Angus C. Russell to Board of Directors 10/31/11 Newswire Story

InterMune to Release Third Quarter Financial Results on November 3 10/27/11 Newswire Story

Get the latest ITMN stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for InterMune, Inc. stock price.

InterMune, Inc. by YCharts

InterMune (ITMN) 14.21 -0.29

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On ITMN

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social